kr229.40
0.78% yesterday
Copenhagen, Dec 04, 04:59 pm CET
ISIN
DK0061802139
Symbol
ALK B

ALK-Abelló Stock price

kr229.40
+21.00 10.08% 1M
+46.60 25.49% 6M
+70.30 44.19% YTD
+65.00 39.54% 1Y
+127.30 124.68% 3Y
+122.10 113.79% 5Y
+185.15 418.42% 10Y
+194.90 564.93% 20Y
Copenhagen, Closing price Thu, Dec 04 2025
-1.80 0.78%
ISIN
DK0061802139
Symbol
ALK B
Industry

Key metrics

Basic
Market capitalization
kr51.5b
Enterprise Value
kr51.3b
Net debt
positive
Cash
kr666.0m
Shares outstanding
221.6m
Valuation (TTM | estimate)
P/E
46.8 | 40.7
P/S
8.5 | 8.0
EV/Sales
8.4 | 7.9
EV/FCF
235.2
P/B
8.3
Dividends
DPS
kr0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
kr6.1b | kr6.5b
EBITDA
kr1.8b | kr1.9b
EBIT
kr1.5b | kr1.6b
Net Income
kr1.1b | kr1.2b
Free Cash Flow
kr218.0m
Growth (TTM | estimate)
Revenue
12.9% | 16.8%
EBITDA
32.9% | 64.9%
EBIT
36.3% | 47.1%
Net Income
40.3% | 53.2%
Free Cash Flow
-71.9%
Margin (TTM | estimate)
Gross
65.9%
EBITDA
29.3% | 30.1%
EBIT
24.2%
Net
18.1% | 19.3%
Free Cash Flow
3.6%
Financial Health
Equity Ratio
65.2%
Return on Equity
15.2%
ROCE
20.9%
ROIC
17.5%
Debt/Equity
0.1
More
EPS
kr4.9
FCF per Share
kr1.0
Short interest
-
Employees
3k
Rev per Employee
kr2.0m
Show more

Is ALK-Abelló a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

ALK-Abelló Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a ALK-Abelló forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a ALK-Abelló forecast:

Buy
85%
Hold
15%

Financial data from ALK-Abelló

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
6,078 6,078
13% 13%
100%
- Direct Costs 2,070 2,070
7% 7%
34%
4,008 4,008
16% 16%
66%
- Selling and Administrative Expenses 1,949 1,949
5% 5%
32%
- Research and Development Expense 587 587
14% 14%
10%
1,781 1,781
33% 33%
29%
- Depreciation and Amortization 309 309
19% 19%
5%
EBIT (Operating Income) EBIT 1,472 1,472
36% 36%
24%
Net Profit 1,101 1,101
40% 40%
18%

In millions DKK.

Don't miss a Thing! We will send you all news about ALK-Abelló directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. The firm manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Peter Halling
Employees 2,753
Founded 1923
Website www.alk.net

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today